Evidence map›Paper›PMID 41874815›Full record

ArticleCerebellum (London, England)2026

Multi-Omics Characterization of a KIF1C Structural Variant in a Patient with a Complex Movement Disorder Partially Responsive to Deep Brain Stimulation.

Mirja Thomsen, Max Borsche, Vicente A Yépez, Dirk Rasche, Kristian K Ullrich, Vera Tadic, Saad M Abdelwakeel, Hauke Busch, Sören Franzenburg, Joanne Trinh and 3 more

Abstract readCase Reports
In one paragraph

Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mirja Thomsen *Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Max Borsche *Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Vicente A YépezSchool of Computation, Information and Technology, Technical University of Munich, Munich, Germany.
Dirk RascheDepartment of Neurosurgery, University of Lübeck, Lübeck, Germany.
Kristian K UllrichDivision Scientific IT Group, Max Planck Institute for Evolutionary Biology, Plön, Germany.
Vera TadicDepartment of Neurology, University of Lübeck, Lübeck, Germany.
Saad M AbdelwakeelMedical Systems Biology Group, University of Lübeck, Lübeck, Germany.
Hauke BuschMedical Systems Biology Group, University of Lübeck, Lübeck, Germany.
Sören FranzenburgInstitute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Joanne TrinhInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Christine KleinInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Katja Lohmann *Institute of Neurogenetics, University of Lübeck, Lübeck, Germany. katja.lohmann@uni-luebeck.de.
Norbert Brüggemann *Institute of Neurogenetics, University of Lübeck, Lübeck, Germany. norbert.brueggemann@uni-luebeck.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biallelic KIF1C variants are associated with a spectrum of neurological phenotypes, including spasticity, cerebellar ataxia, chorea, and dystonia. Most reported patients involve single-nucleotide variants, whereas copy number variants (CNVs) have been described only once in the PubMed-listed literature. The therapeutic potential of deep-brain stimulation (DBS) in KIF1C-related disease has not yet been evaluated. We report a patient presenting with spasticity, ataxia, dystonia, and head tremor, in whom prior exome sequencing was inconclusive. A multi-omics approach was applied, including optical genome mapping (OGM), genome sequencing, and transcriptome sequencing. The clinical effect of DBS was assessed. OGM revealed a homozygous KIF1C Exon 17–18 deletion, retrospectively detectable in exome and genome data but initially missed by sequence analysis. Transcriptome sequencing demonstrated significantly reduced KIF1C expression and absence of normally spliced transcripts around those exons, consistent with a loss-of-function mechanism. DBS led to partial clinical improvement, with notable reduction of dystonia and head tremor. Structural variants may be an underrecognized cause of complex movement disorders involving spasticity, ataxia, and dystonia. Diagnostic methods specifically targeting structural variation, such as OGM or CNV analysis of short-read data, can be essential for diagnosis. Transcriptome data add valuable functional insight. This report also suggests that DBS may offer symptomatic benefit in KIF1C-associated disease, particularly for dystonic signs.

Indexed as

Deep Brain StimulationKinesinsMovement DisordersFemaleHumansMaleMultiomicsKIF1C protein, humanKinesinsAtaxiaDystoniaGene dosage changeHard-to-detect variantHead tremorKIF1CLeukoencephalopathyMyoclonusOptical genome mappingQuadruple DBSRare neurological diseaseSpastic ataxia type 2 (OMIM: 611302)SpasticityTranscriptome

Identifiers

PMID41874815
PMCPMC13013209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.